DK1297825T3 - Faste orale dosisformer af simethicon - Google Patents

Faste orale dosisformer af simethicon

Info

Publication number
DK1297825T3
DK1297825T3 DK02256741T DK02256741T DK1297825T3 DK 1297825 T3 DK1297825 T3 DK 1297825T3 DK 02256741 T DK02256741 T DK 02256741T DK 02256741 T DK02256741 T DK 02256741T DK 1297825 T3 DK1297825 T3 DK 1297825T3
Authority
DK
Denmark
Prior art keywords
simethicone
dosage forms
oral dosage
solid oral
solid
Prior art date
Application number
DK02256741T
Other languages
Danish (da)
English (en)
Inventor
Christopher E Szymczak
James T Walter
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Application granted granted Critical
Publication of DK1297825T3 publication Critical patent/DK1297825T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02256741T 2001-09-28 2002-09-27 Faste orale dosisformer af simethicon DK1297825T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form
EP02256741A EP1297825B1 (de) 2001-09-28 2002-09-27 Feste orale Dosierungsform von Simethicon

Publications (1)

Publication Number Publication Date
DK1297825T3 true DK1297825T3 (da) 2005-09-26

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02256741T DK1297825T3 (da) 2001-09-28 2002-09-27 Faste orale dosisformer af simethicon

Country Status (18)

Country Link
US (3) US7101573B2 (de)
EP (1) EP1297825B1 (de)
AR (1) AR036700A1 (de)
AT (1) ATE296619T1 (de)
AU (1) AU2002301259C1 (de)
BR (1) BR0204001A (de)
CA (1) CA2405190C (de)
CO (1) CO5390073A1 (de)
DE (1) DE60204403T2 (de)
DK (1) DK1297825T3 (de)
ES (1) ES2243664T3 (de)
HU (1) HUP0203176A2 (de)
MX (1) MXPA02009570A (de)
NZ (1) NZ521657A (de)
PL (1) PL204141B1 (de)
PT (1) PT1297825E (de)
RU (1) RU2362569C2 (de)
ZA (1) ZA200207755B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
EP1509204A4 (de) * 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co Agglomerierte teilchen mit einem wirkstoff, der zusammen mit verkieselter mikrokristalliner cellulose aufbereitet wird
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (de) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolämische Zusammensetzungen enthaltend ein Statin und ein Antiflatulenzmittel
RU2384339C2 (ru) * 2004-04-13 2010-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Применение симетикона для предрасположенных к запорам пациентов
US20080255104A1 (en) * 2004-05-04 2008-10-16 Equitech Corporation Nsaid Compositions
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
EP1862184A4 (de) * 2005-03-24 2012-12-19 Daiichi Sankyo Co Ltd Pharmazeutische zusammensetzung
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
EP2486910A3 (de) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Vorrichtung mit mehreren Kammern und Dispenser
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
AU2007323674B2 (en) 2006-11-21 2013-05-23 Mcneil-Ppc, Inc. Modified release analgesic suspensions
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
EP2252274A4 (de) 2008-02-20 2011-05-11 Univ Missouri Zusammensetzung mit einer kombination aus omeprazol und lansoprazol und puffermittel sowie anwendungsverfahren
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2727746T3 (es) 2009-01-06 2019-10-18 Galenagen Llc Composiciones orales para el tratamiento o la prevención de infecciones por E. Coli
NZ593831A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (ja) * 2009-04-09 2014-02-05 ライオン株式会社 木クレオソート含有固形製剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
JP2014516080A (ja) 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
IN2014DN01619A (de) 2011-09-08 2015-05-15 Novartis Ag
CA2853520C (en) * 2011-10-27 2021-11-16 Thomas Julius Borody Electrolyte purgatives
ITMI20112221A1 (it) * 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
AU2012327176B2 (en) 2011-12-14 2015-08-13 Disphar International B.V. Simethicone formulation
RU2491941C1 (ru) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Композиционный энтеросорбент
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
JP6724537B2 (ja) * 2015-05-26 2020-07-15 大正製薬株式会社 固形製剤
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
EP3294269A1 (de) 2015-06-12 2018-03-21 Santa Farma Ilaç Sanayi A.S. Orale pharmazeutische zusammensetzung mit einem otilonium-bromid und simethicon mit einer bestimmten schüttdichte und verbesserten lösungseigenschaften
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
MX2016016587A (es) * 2016-12-14 2018-06-13 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
CA3076413A1 (en) 2017-09-29 2019-04-04 Johnson & Johnson Consumer Inc. Solid simethicone particles and dosage form thereof
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780B1 (fr) * 2020-12-22 2024-04-05 Oreal Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5073384A (en) 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
IN171919B (de) 1989-11-01 1993-02-06 Mcneil Ppc Inc
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (ja) 1991-10-08 2001-06-18 堀井薬品工業株式会社 消化管内ガス除去剤
JP3378004B2 (ja) * 1992-04-30 2003-02-17 塩野義製薬株式会社 経口懸濁製剤用の安定な水和セファロスポリン乾燥粉末
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (fr) 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
JPH09504293A (ja) * 1993-10-28 1997-04-28 ザ、プロクター、エンド、ギャンブル、カンパニー マグネシウムアルミニウムシリケート及び複数の活性成分を含有した速溶解性剤形
DE69426863T2 (de) 1993-12-15 2001-09-27 Nat Starch Chem Invest Verwendung von Öl adsorbierenden natürlichen Polymeren in kosmetischen und pharmazeutischen Anwendungen
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Also Published As

Publication number Publication date
HU0203176D0 (de) 2002-11-28
US20100135982A1 (en) 2010-06-03
US20070196468A1 (en) 2007-08-23
AU2002301259B2 (en) 2009-01-22
US7691409B2 (en) 2010-04-06
AU2002301259C1 (en) 2009-07-23
PL356358A1 (en) 2003-04-07
ATE296619T1 (de) 2005-06-15
US20030091624A1 (en) 2003-05-15
EP1297825B1 (de) 2005-06-01
US7101573B2 (en) 2006-09-05
EP1297825A1 (de) 2003-04-02
CA2405190A1 (en) 2003-03-28
AR036700A1 (es) 2004-09-29
PT1297825E (pt) 2005-08-31
RU2002125821A (ru) 2004-03-27
ES2243664T3 (es) 2005-12-01
BR0204001A (pt) 2003-09-16
RU2362569C2 (ru) 2009-07-27
NZ521657A (en) 2004-05-28
DE60204403D1 (de) 2005-07-07
CA2405190C (en) 2010-11-09
CO5390073A1 (es) 2004-04-30
HUP0203176A2 (hu) 2004-07-28
MXPA02009570A (es) 2004-07-30
ZA200207755B (en) 2004-03-26
PL204141B1 (pl) 2009-12-31
DE60204403T2 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
DK1297825T3 (da) Faste orale dosisformer af simethicon
DE60109207D1 (de) Orale zusammensetzung
DK1417180T3 (da) Fremstilling af aminopyrimidinforbindelser
DK1674084T3 (da) Forlænget frigivelse af oral dosissammensætning
DE60223654D1 (de) Resistzusammensetzung
DK1438306T3 (da) Derivater af UK-2A
DE60143178D1 (de) Lichtempfindliche Zusammensetzung
ATE353627T1 (de) Stabilisierte orale suspensionsformulierung
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
NO20040125L (no) Enterale formuleringer
FI20011478A (fi) Farmaseuttinen koostumus
EE05020B1 (et) Glburiidi ravimkoostis
DE10196204T1 (de) Orale Vorrichtungen
IS7051A (is) Lyfjasamsetningar
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60326998D1 (de) Orale zubereitung
NO20041968L (no) Anvendelse av cystationin
NO20040857L (no) Ny oral forlenget frigivelses doseringsform.
NO20040966D0 (no) Orale vaksiner.
FI20011778A (fi) Ryhmälähetyksen toteutus
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
DE60223828D1 (de) Spermizide
NO20040866L (no) Ny oral forlenget frigivelses doseringsform
DE50209548D1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl-but-2-enylaminverbindungen